{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:37:36Z","timestamp":1791632256197,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005930","name":"Research Foundation Mental health services","doi-asserted-by":"publisher","award":["R01AA025071"],"award-info":[{"award-number":["R01AA025071"]}],"id":[{"id":"10.13039\/100005930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physiology &amp; Behavior"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.physbeh.2019.03.029","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T20:13:10Z","timestamp":1554149590000},"page":"232-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review"],"prefix":"10.1016","volume":"206","author":[{"given":"Amanda","family":"Brunchmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7143-1236","authenticated-orcid":false,"given":"Anders","family":"Fink-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.physbeh.2019.03.029_bb0005","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/WNR.0000000000001071","article-title":"Accumbal ghrelin and glucagon-like peptide 1 signaling in alcohol reward in female rats","volume":"29","author":"Abtahi","year":"2018","journal-title":"NeuroReport"},{"issue":"2","key":"10.1016\/j.physbeh.2019.03.029_bb0010","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus Accumbens to control for food intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"issue":"7\u20138","key":"10.1016\/j.physbeh.2019.03.029_bb0015","first-page":"8","article-title":"Methadone treatment of opiate addiction: a systematic review of comparative studies","volume":"14","author":"Ali","year":"2017","journal-title":"Innov. Clin. Neurosci."},{"issue":"7","key":"10.1016\/j.physbeh.2019.03.029_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019562","article-title":"Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial","volume":"8","author":"Antonsen","year":"2018","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.physbeh.2019.03.029_bb0025","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain","volume":"4","author":"Cork","year":"2015","journal-title":"Mol. Metab."},{"issue":"3","key":"10.1016\/j.physbeh.2019.03.029_bb0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/pr.115.011668","article-title":"Evaluation of the &quot;Pipeline&quot; for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research","volume":"68","author":"Czoty","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"8","key":"10.1016\/j.physbeh.2019.03.029_bb0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/pdi.1978","article-title":"The role of GLP-1 receptor agonists as weight loss agents in patients with and without type 2 diabetes","volume":"32","author":"Dar","year":"2015","journal-title":"Pract. Diabetes"},{"issue":"5","key":"10.1016\/j.physbeh.2019.03.029_bb0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.biopsych.2012.01.035","article-title":"Gastric bypass surgery attenuates ethanol consumption in ethanol-preferring rats","volume":"72","author":"Davis","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.physbeh.2019.03.029_bb0045","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J. Clin. Investig."},{"issue":"7","key":"10.1016\/j.physbeh.2019.03.029_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069010","article-title":"The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.physbeh.2019.03.029_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077284","article-title":"The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.physbeh.2019.03.029_bb0060","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents","volume":"38","author":"Egecioglu","year":"2012","journal-title":"Psychoneuroendocrinology"},{"issue":"11","key":"10.1016\/j.physbeh.2019.03.029_bb0065","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/j.1460-9568.1995.tb00650.x","article-title":"Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites","volume":"7","author":"G\u00f6ke","year":"1995","journal-title":"Eur. J. Neurosci."},{"issue":"9","key":"10.1016\/j.physbeh.2019.03.029_bb0070","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/mp.2012.141","article-title":"GLP-1 analog attenuates cocaine reward","volume":"18","author":"Graham","year":"2013","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.physbeh.2019.03.029_bb0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00213-008-1079-x","article-title":"Controversies in translational research: drug self-administration","volume":"199","author":"Haney","year":"2008","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.physbeh.2019.03.029_bb0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/en.2014-1675","article-title":"Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain","volume":"156","author":"Heppner","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.physbeh.2019.03.029_bb0085","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.physbeh.2019.03.029_bb0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/adb.12583","article-title":"Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats","volume":"24","author":"Hernandez","year":"2019","journal-title":"Addict. Biol."},{"issue":"9","key":"10.1016\/j.physbeh.2019.03.029_bb0095","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/ijo.2012.208","article-title":"Incretin hormones and the satiation signal","volume":"37","author":"Holst","year":"2013","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.physbeh.2019.03.029_bb0100","series-title":"SYRCLE's risk of bias tool for animal studies","author":"Hooijmans","year":"2014"},{"key":"10.1016\/j.physbeh.2019.03.029_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2018.01.013","article-title":"GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence","author":"Jerlhag","year":"2018","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.physbeh.2019.03.029_bb0115","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1289\/ehp.1206389","article-title":"Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review","volume":"121","author":"Krauth","year":"2013","journal-title":"Environ. Health Perspect."},{"issue":"2","key":"10.1016\/j.physbeh.2019.03.029_bb0120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","article-title":"Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system","volume":"403","author":"Merchenthaler","year":"1999","journal-title":"J. Comp. Neurol."},{"issue":"5","key":"10.1016\/j.physbeh.2019.03.029_bb0125","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg. (London, England)"},{"issue":"7","key":"10.1016\/j.physbeh.2019.03.029_bb0130","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/npp.2015.362","article-title":"Glucagon-like Peptide-1 receptor activation in the ventral tegmental area decreases the reinforcing efficacy of cocaine","volume":"41","author":"Schmidt","year":"2016","journal-title":"Neuropsychopharmacol. Off. Pub. Am. Coll. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.physbeh.2019.03.029_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061965","article-title":"Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward","volume":"8","author":"Shirazi","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.physbeh.2019.03.029_bb0140","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.physbeh.2016.04.013","article-title":"Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors","volume":"161","author":"Sirohi","year":"2016","journal-title":"Physiol. Behav."},{"issue":"10","key":"10.1016\/j.physbeh.2019.03.029_bb0145","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/acer.13199","article-title":"Effects of the GLP-1 agonist Exendin-4 on intravenous ethanol self-Administration in Mice","volume":"40","author":"S\u00f8rensen","year":"2016","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.physbeh.2019.03.029_bb0150","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice","volume":"149","author":"S\u00f8rensen","year":"2015","journal-title":"Physiol. Behav."},{"issue":"12","key":"10.1016\/j.physbeh.2019.03.029_bb0160","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/14656566.2017.1349098","article-title":"Pharmacotherapy of alcoholism - an update on approved and off-label medications","volume":"18","author":"Soyka","year":"2017","journal-title":"Expert. Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.physbeh.2019.03.029_bb0165","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1038\/tp.2015.68","article-title":"The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.physbeh.2019.03.029_bb0170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/jpet.117.241141","article-title":"Effects of acute and chronic treatments with dopamine D 2 and D 3 receptor ligands on cocaine versus food choice in rats","volume":"362","author":"Thomsen","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.physbeh.2019.03.029_bb0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pbb.2017.07.014","article-title":"The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice","volume":"160","author":"Thomsen","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"5","key":"10.1016\/j.physbeh.2019.03.029_bb0180","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.physbeh.2019.03.029_bb0185","series-title":"Trends in Organized Crime (Vol. 3)","article-title":"World drug report. Analysis of drug markets","author":"UNDOC","year":"2018"},{"issue":"2","key":"10.1016\/j.physbeh.2019.03.029_bb0190","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/adb.12295","article-title":"The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents","volume":"21","author":"Vall\u00f6f","year":"2016","journal-title":"Addict. Biol."},{"key":"10.1016\/j.physbeh.2019.03.029_bb0195","series-title":"Global Status Report on Alcohol and Health 2014","article-title":"WHO","author":"WHO","year":"2016"},{"key":"10.1016\/j.physbeh.2019.03.029_bb0200","series-title":"Information Sheet on Opioid Overdose","author":"WHO","year":"2018"},{"key":"10.1016\/j.physbeh.2019.03.029_bb0205","series-title":"WHO report on the global tobacco epidemic 2017","article-title":"WHO","author":"WHO","year":"2017"}],"container-title":["Physiology &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938418308485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938418308485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:10:01Z","timestamp":1758478201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031938418308485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":39,"alternative-id":["S0031938418308485"],"URL":"https:\/\/doi.org\/10.1016\/j.physbeh.2019.03.029","relation":{},"ISSN":["0031-9384"],"issn-type":[{"value":"0031-9384","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Physiology & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.physbeh.2019.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}